miRagen Therapeutics
NASDAQ: VRDNBoulder, US · Delaware corporation · 3 known investors
Discovers and develops microRNA-targeting therapies for areas of high unmet medical need.
Biotech
Founders & leadership
TH
Thomas HughesDirector
MC
Marvin CaruthersDirector
CJ
Christopher J MorlExecutive Officer
BB
Bruce BoothExecutive Officer, Director
JA
Jason A. LeveroneExecutive Officer
DR
David RodmanExecutive Officer
JC
John CreecyDirector
WS
William S. MarshallExecutive Officer, Director
CB
Christopher BowdenDirector
PD
Paul D. RubinExecutive Officer
JL
Joseph L. TunerDirector
JS
Jeffrey S. HatfieldDirector
Investors · 3
Reported raises · per SEC filings
Form D private placements▶$91MraisedNov 2020 · 22 investors · BiotechnologyRule 506(b)
▶$91MraisedNov 2020 · 22 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Joesph L. TurnerDirector
- Jonathan ViolinExecutive Officer
- Lee M RauchExecutive Officer, Director
- Jason A. LeveroneExecutive Officer
- Diana EscolarExecutive Officer
- Jeffrey S HatfieldDirector
- Peter E. HarwinDirector
- Tomas KiselakDirector
- Arlene M. MorrisDirector
- Offering amount
- $91M
- Amount sold
- $91M
- Finders' fees
- $4.5M
- Placement agents
- Jefferies LLC, JMP Securities LLC
- First sale
- Oct 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.5MraisedOct 2019 · 1 investors · BiotechnologyRule 506(b)
▶$1.5MraisedOct 2019 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- William S. MarshallExecutive Officer, Director
- Jason A. LeveroneExecutive Officer
- Joseph L. TurnerDirector
- Arlene M. MorrisDirector
- Kevin KochDirector
- Thomas E. HughesDirector
- Jeffrey S. HatfieldDirector
- Christopher BowdenDirector
- Paul D. RubinExecutive Officer
- Offering amount
- $5M
- Amount sold
- $1.5M
- First sale
- Aug 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$172.3KraisedNov 2017 · 1 investors · BiotechnologyRule 506(b)
▶$172.3KraisedNov 2017 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jason A. LeveroneExecutive Officer
- Christopher BowdenDirector
- Paul D. RubinExecutive Officer
- Joseph L. TunerDirector
- Jeffrey S. HatfieldDirector
- Bruce L. BoothDirector
- Adam S. LevyExecutive Officer
- Thomas E. HughesDirector
- William S. MarshallExecutive Officer, Director
- Kevin KochDirector
- Offering amount
- $172.3K
- Amount sold
- $172.3K
- First sale
- Nov 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$40.7MraisedFeb 2017 · 25 investors · BiotechnologyRule 506(b)
▶$40.7MraisedFeb 2017 · 25 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- John W. CreecyDirector
- Jason A LeveroneExecutive Officer
- Kevin KochDirector
- Thomas E. HughesDirector
- William S. MarshallExecutive Officer, Director
- Adam S LevyExecutive Officer
- Kyle A. LefkoffDirector
- Bruce L. BoothDirector
- Paul D. RubinExecutive Officer
- Offering amount
- $40.7M
- Amount sold
- $40.7M
- Sales commissions
- $1.2M
- Placement agents
- Wedbush Securities Inc.
- First sale
- Feb 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$25MraisedNov 2015 · 34 investors · BiotechnologyRule 506(b)
▶$25MraisedNov 2015 · 34 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Thomas E HughesDirector
- Kyle LefkoffDirector
- Marvin H CaruthersDirector
- David RodmanExecutive Officer
- William S. MarshallExecutive Officer, Director
- Joshua ResnickDirector
- John CreecyDirector
- Jason A LeveroneExecutive Officer
- Bruce L BoothExecutive Officer, Director
- Christopher J MorlExecutive Officer
- Offering amount
- $41.1M
- Amount sold
- $25M
- First sale
- Oct 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$8.5MraisedFeb 2015 · 29 investors · BiotechnologyRule 506(b)
▶$8.5MraisedFeb 2015 · 29 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Thomas HughesDirector
- Marvin CaruthersDirector
- Kyle LefkoffDirector
- Christopher J MorlExecutive Officer
- Bruce BoothExecutive Officer, Director
- Jason A LeveroneExecutive Officer
- David RodmanExecutive Officer
- John CreecyDirector
- William S. MarshallExecutive Officer, Director
- Offering amount
- $20M
- Amount sold
- $8.5M
- First sale
- Feb 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.